BC Innovations | Apr 5, 2019
Tools & Techniques

Second shot for shRNA

Having long been demoted to tool compound status, shRNA is gaining renewed attention as a therapeutic modality by offering a simpler path to creating next-generation cell therapies than gene editing. Celyad has jumped in, using...
BC Week In Review | Dec 21, 2018
Clinical News

Benitec's BB-401 misses Stage 1 response threshold in Phase II for head and neck cancer

Benitec Biopharma Ltd. (ASX:BLT; NASDAQ:BNTC) said an initial analysis of the 12-patient Stage 1 cohort in a Phase II trial to treat recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) showed...
Items per page:
1 - 2 of 2